Do analysts recommend PPCB or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, PPCB or ZVSA?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is PPCB or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% ZyVersa Therapeutics N/A -109.54% -43.95%

Does the media favor PPCB or ZVSA?

In the previous week, Propanc Biopharma had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 3 mentions for Propanc Biopharma and 1 mentions for ZyVersa Therapeutics. Propanc Biopharma's average media sentiment score of 0.30 beat ZyVersa Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ZyVersa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GOVX or ZVSA?

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 20,414.22%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% ZyVersa Therapeutics N/A -109.54% -43.95%

Does the media prefer GOVX or ZVSA?

In the previous week, GeoVax Labs had 3 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for GeoVax Labs and 1 mentions for ZyVersa Therapeutics. GeoVax Labs' average media sentiment score of 0.22 beat ZyVersa Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ZyVersa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DCOY or ZVSA?

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, DCOY or ZVSA?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is DCOY or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts prefer ZVSA or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ZVSA or LABT?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A -$2.00 N/A

Is ZVSA or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Is VCNX or ZVSA more profitable?

Vaccinex's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% ZyVersa Therapeutics N/A -109.54% -43.95%

ZyVersa Therapeutics (ZVSA) Competitors

$0.12 +0.01 (+5.45%)

As of 07/24/2026 02:39 PM Eastern

Compare

ZVSA vs. PPCB, GOVX, DCOY, LABT, and VCNX

Should you buy ZyVersa Therapeutics stock or one of its competitors? MarketBeat compares ZyVersa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZyVersa Therapeutics include Propanc Biopharma (PPCB), GeoVax Labs (GOVX), Decoy Therapeutics (DCOY), Lakewood-Amedex Biotherapeutics (LABT), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Propanc Biopharma had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 3 mentions for Propanc Biopharma and 1 mentions for ZyVersa Therapeutics. Propanc Biopharma's average media sentiment score of 0.30 beat ZyVersa Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ZyVersa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Propanc Biopharma has a beta of 3.49, suggesting that its stock price is 249% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Summary

Propanc Biopharma beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, GeoVax Labs had 3 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for GeoVax Labs and 1 mentions for ZyVersa Therapeutics. GeoVax Labs' average media sentiment score of 0.22 beat ZyVersa Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ZyVersa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 20,414.22%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics has lower revenue, but higher earnings than GeoVax Labs. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.02	-$21.47M	-$19.12	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Summary

GeoVax Labs beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Decoy Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for ZyVersa Therapeutics. Decoy Therapeutics' average media sentiment score of 1.44 beat ZyVersa Therapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
ZyVersa Therapeutics	Neutral

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Decoy Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

ZyVersa Therapeutics' return on equity of -109.54% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Summary

Decoy Therapeutics beats ZyVersa Therapeutics on 8 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Lakewood-Amedex Biotherapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Lakewood-Amedex Biotherapeutics had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for ZyVersa Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.94 beat ZyVersa Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZyVersa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Summary

Lakewood-Amedex Biotherapeutics beats ZyVersa Therapeutics on 5 of the 9 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, ZyVersa Therapeutics had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for ZyVersa Therapeutics and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
ZyVersa Therapeutics	Neutral

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Vaccinex's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

ZyVersa Therapeutics has lower revenue, but higher earnings than Vaccinex. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Summary

Vaccinex beats ZyVersa Therapeutics on 6 of the 10 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$921K	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-0.14	21.29	27.14	23.63
Price / Sales	N/A	297.82	582.30	111.98
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	0.03	7.88	10.28	6.01
Net Income	-$9.41M	$23.86M	$3.60B	$331.99M
7 Day Performance	0.87%	-3.82%	-1.27%	-0.63%
1 Month Performance	-37.93%	-4.45%	-1.67%	-3.04%
1 Year Performance	-57.04%	33.01%	18.25%	13.30%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.12 +5.5%	N/A	-57.0%	$921K	N/A	N/A	2	News Coverage Gap Down
PPCB Propanc Biopharma	0.4633 of 5 stars	$1.59 -2.5%	N/A	-99.1%	$3.71M	N/A	N/A	1	Positive News Short Interest Increase Gap Up
GOVX GeoVax Labs	2.0899 of 5 stars	$0.87 -13.8%	$150.00 +17,133.5%	-96.3%	$3.51M	$2.49M	N/A	10	Positive News Upcoming Earnings Short Interest Increase Gap Down High Trading Volume
DCOY Decoy Therapeutics	3.0089 of 5 stars	$5.99 -3.1%	$30.00 +400.8%	N/A	$3.29M	N/A	N/A	20	Short Interest Decrease
LABT Lakewood-Amedex Biotherapeutics	0.838 of 5 stars	$1.85 -23.9%	N/A	N/A	$3.24M	N/A	N/A	5	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. PPCB, GOVX, DCOY, LABT, and VCNX

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Summary

How does ZyVersa Therapeutics compare to Decoy Therapeutics?

Summary

How does ZyVersa Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Summary

How does ZyVersa Therapeutics compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. PPCB, GOVX, DCOY, LABT, and VCNX

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Which has better valuation and earnings, PPCB or ZVSA?

Do insiders & institutionals hold more shares of PPCB or ZVSA?

Do analysts recommend PPCB or ZVSA?

Does the media favor PPCB or ZVSA?

Is PPCB or ZVSA more profitable?

Which has more volatility & risk, PPCB or ZVSA?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Does the media prefer GOVX or ZVSA?

Is GOVX or ZVSA more profitable?

Do analysts rate GOVX or ZVSA?

Which has higher earnings & valuation, GOVX or ZVSA?

Do insiders and institutionals believe in GOVX or ZVSA?

Which has more risk and volatility, GOVX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Decoy Therapeutics?

Which has preferable valuation & earnings, DCOY or ZVSA?

Do insiders & institutionals believe in DCOY or ZVSA?

Does the media prefer DCOY or ZVSA?

Do analysts rate DCOY or ZVSA?

Which has more volatility and risk, DCOY or ZVSA?

Is DCOY or ZVSA more profitable?

Summary

How does ZyVersa Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Which has better valuation & earnings, ZVSA or LABT?

Do institutionals and insiders believe in ZVSA or LABT?

Does the media refer more to ZVSA or LABT?

Do analysts prefer ZVSA or LABT?

Is ZVSA or LABT more profitable?

Summary

How does ZyVersa Therapeutics compare to Vaccinex?

Does the media refer more to VCNX or ZVSA?

Do insiders & institutionals hold more shares of VCNX or ZVSA?

Which has more volatility and risk, VCNX or ZVSA?

Is VCNX or ZVSA more profitable?

Which has higher earnings & valuation, VCNX or ZVSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools